Glioma clinical trials in New York
28 studies for Glioma are looking for participants at sites in New York.
Cities in New York
- New York City25 studies
- Queens7 studies
- New Rochelle5 studies
- Greenburgh4 studies
- Staten Island4 studies
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
- and 4 more
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Oct 1, 2026 · NCT05099003Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Northwell Health Center for Advanced Medicine - Brain Tumor Center, Lake Success
- Columbia University Irving Medical Center, New York
- Montefiore Medical Center, The Bronx
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07326566A Study of Mirdametinib in People With Central Nervous System Tumors
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07539441Glioma Developmental and HyperActive Ras Tumor (DHART) Board
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering West Harrison (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT05489783SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- New York University, New York
RecruitingPhase 1
Ages 1 to 25 · All sexes · Updated Aug 18, 2026 · NCT04485559Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, New York
- Research Site, New York
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 12, 2026 · NCT05417594Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
- New York Presbyterian Hospital-Columbia University Medical Center, New York
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07486713A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
- NYU Langone Health, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07464925A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
- Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05188508Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
- NYU Langone Health, New York
Recruiting
Ages 18 to 85 · All sexes · Updated Jul 21, 2026 · NCT06910306MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 1 to 26 · All sexes · Updated Jul 10, 2026 · NCT06712875Chronic CED of TPT for Recurrent Malignant Glioma
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 15, 2026 · NCT06666712A Study of 177Lu-PSMA-617 in People With Gliomas
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT07223034Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
- Lenox Hill Brain Tumor Center, New York
Recruiting
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT05954858Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- Lenox Hill Brain Tumor Center, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT05271240Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
- Lenox Hill Brain Tumor Center, New York
Recruiting
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT05979064A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- Roswell Park, Buffalo
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Columbia University Medical Center, New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06326411Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
- Memorial Sloan Kettering, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT06126744Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06810544Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- Lenox Hill Brain Tumor Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT02800486DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
- Northwell Health, Lake Success
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 11, 2026 · NCT06504381FUS Etoposide for DMG
- Columbia University Irving Medical Center, New York
RecruitingPhase 1
Ages 4 to 21 · All sexes · Updated Jan 28, 2026 · NCT05762419Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
- NYU Langone Health, New York
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jan 2, 2026 · NCT06829173Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma
- University of Rochester, Rochester
Recruiting
Ages 18 and older · All sexes · Updated Dec 18, 2025 · NCT04543201Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- Memorial Sloan Kettering Cancer Center, New York
Recruiting
Ages 18 and older · All sexes · Updated Oct 10, 2025 · NCT00870129Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- Northshore University Hospital, Manhasset
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 26, 2025 · NCT01906385From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.